Rare disease Day San Diego

By Nancy Werner

September 19, 2014 (San Diego)-Most people familiar with drug research think of Boston as the center for leading drug research, but San Diego leads in research and development into RNA therapies and treatments that bring hope for patients with rare diseases like mesothelioma.RNA Drug Development for Rare Diseases Booming in San Diego

San Diego is fast becoming a center for RNA therapy research, writes Joseph Payne, CEO of the biotech development firm Acturus Therapeutics, in Xconomy, an online news site that focuses on business and technology. In addition to his own company, Isis Pharmaceuticals, Santaris Pharma, Regulus Therapeutics, and Solstice Neurosciences are also developing RNA therapies.

RNA treatments work by interfering with the development of cells that would otherwise carry a disease, specifically disrupt their RNA (ribonucleic acid). If you remember your high school chemistry class, RNA is one of the basic building blocks of life. When the RNA in cells that are up to no good gets disrupted, they can’t continue to support the disease.

Treatment for Peritoneal Mesothelioma at Moores Cancer Center, UC San Diego

San Diego also has several cancer centers that offer treatments that may help patients with mesothelioma. One such center is Moores Cancer Center at UC-San Diego, which offers a treatment for many patients with peritoneal mesothelioma, states MesotheliomaHelp.org.

About 25 percent of all mesothelioma patients have this form of the disease, according to the American Cancer Society. Like other peritoneal (abdominal) cancers, it is difficult to treat. Moores offers HIPEC—heated intraperitoneal chemoperfusion—a treatment many oncologists recommend for patients with advanced peritoneal cancer. Also called “hot therapy, ” it is performed during surgery, after visible tumors have been removed, to destroy any remaining cancer cells. According to the Moores website, it has shown substantial clinical evidence as an effective treatment for peritoneal mesothelioma.

MED-21. Spontaneous intramural small bowel hemorrhage: a rare complication of anti-coagulation.(Section on Internal Medicine): An article from: Southern Medical Journal
Book (Southern Medical Association)
Related Posts